Cord blood cells engineered to fight lung cancer enter human testing

NCT ID NCT05334329

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This early-phase trial tests a new treatment for people with advanced non-small cell lung cancer that has stopped responding to standard immunotherapy. The treatment uses immune cells from umbilical cord blood that are genetically modified to better recognize and attack cancer cells. Some participants also receive an additional immunotherapy drug called atezolizumab. The main goal is to check safety and find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
umbilical cord blood natural killer cells (COH06) with or without atezolizumab
What this could lead to
If this works, it could point toward a new treatment option for advanced lung cancer patients whose cancer no longer responds to standard immunotherapy.
What could go wrong
This is a very early, small Phase 1 trial with only 6 participants, focused mainly on safety and dosing. The approach may not shrink tumors or work for everyone, and there are risks of side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chao Family Comprehensive Cancer Center University of California, Irvine

    Orange, California, 92868, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.